Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Health
Related: About this forumWHY IS NO ONE ON THE FIRST TREATMENT TO PREVENT H.I.V.?
http://www.newyorker.com/online/blogs/elements/2013/10/the-battle-over-truvada-and-the-first-treatment-to-prevent-hiv.htmlIn November, 2010, the New England Journal of Medicine published the results of a three-year clinical trial, funded by the National Institutes of Health, announcing the arrival of a treatment that could reduce the risk of contracting H.I.V. by more than ninety per cent. The treatment involved a blue, oval pill containing emtricitabine and tenofovir. Marketed under the brand name Truvada, the pill was synthesized in 2004 by Gilead Sciences, the worlds largest producer of branded H.I.V. drugs, and has been used in combination with other antiretrovirals as a primary treatment for people living with AIDS. The N.I.H. team discovered that a daily dose of Truvada not only suppressed the virus in people who were already infected but also prevented healthy people from contracting H.I.V. in the first place. Following the N.I.H. study, which tracked gay men in Peru, Ecuador, Brazil, South Africa, Thailand, and the United States, additional trials showed the drug to be effective for heterosexual men and women, as well as for injection-drug users. Researchers called the treatment pre-exposure prophylaxis, or PrEP for short. Others have called it the new condom.
On the day the N.I.H. announced the results of the PrEP study, the research team received a congratulatory phone call from President Obama. Shortly thereafter, Time put PrEP in the first slot on its list of the years top medical innovations. Dr. Robert Grant, a professor at the University of California San Francisco and the N.I.H. studys lead scientist, braced for a stampede. He told me, The evening before we announced, we had meetings with the leadership of public health in California, and they were thinking, as we were, that there was going to be a rush, that everyone was going to descend on the clinics. The Centers for Disease Control issued interim usage guidelines, despite the fact that the treatment was more than a year away from formal F.D.A. approval. The C.D.C. knew that some doctors were already prescribing Truvada for prevention off-label, and it expected more to follow suit.
But, in fact, adoption of the drug has been slow. According to Dawn Smith, a biomedical interventions implementation officer in the C.D.C.s epidemiology branch, at least half a million Americans are good candidates for PrEPmeaning that they are at high risk for contracting H.I.V. through sexual activityyet only a few thousand Americans are receiving the treatment. As in most fields, many clinicians dont want to be the first one out of the gate, Smith said. Salim Karim, the chair of United Nations AIDS Scientific Expert Panel and the director of the Centre for the AIDS Programme of Research in South Africa, thinks that doctors hesitance may not have anything to do with sexual health. Clinicians fundamentally have difficulty giving healthy people drugs, he said. This is not unique to H.I.V. Meanwhile, despite repeated demonstrations that Truvada provides protection from H.I.V., an estimated hundred and fifty thousand Americans, more than a third of whom are in their teens and twenties, have become infected with the virus since the results of the study were released.
The medical communitys reluctance to prescribe Truvadaand patients reluctance to request italso stems from a bitter fight over the treatment. Critics have questioned PrEPs safety, efficacy, and cost, and accusing the government of colluding with the drug manufacturer at the expense of public health. Regan Hofmann, the former editor-in-chief of Poz, a magazine for people living with AIDS, called PrEP a profit-driven sex toy for rich Westerners. Michael Weinstein, the head of the AIDS Healthcare Foundation (A.H.F.), the worlds largest AIDS organization and the primary-care provider for more than two hundred thousand patients around the world, predicted a public-health catastrophe. The applause for this approach shows just how disposable we consider the lives of gay men, he wrote. When I interviewed Weinstein, he claimed the studies were rigged and that PrEP was essentially a plot by Gilead to force young people into buying unnecessary medication, and that it was going badly because A.H.F. wasnt letting the company get away with it.
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
2 replies, 1078 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (0)
ReplyReply to this post
2 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
WHY IS NO ONE ON THE FIRST TREATMENT TO PREVENT H.I.V.? (Original Post)
xchrom
Oct 2013
OP
pipoman
(16,038 posts)1. I.V. drug users and people
partaking in risky sex likely don't have the money nor the inclination to take such a drug.
Turbineguy
(37,369 posts)2. They cost about $25 per pill.